title: The role of prothrombin complex concentrates in reversal of target specific anticoagulants.
abstract: Over the past several years a new era for patients requiring anticoagulation has arrived. The approval of new target specific oral anticoagulants offers practitioners several advantages over traditionally used vitamin K antagonist agents including predictable pharmacokinetics, rapid onset of action, comparable efficacy and safety, all without the need for routine monitoring. Despite these benefits, hemorrhagic complicates are inevitable with any anticoagulation treatment. One of the major disadvantages of the new oral anticoagulants is lack of specific antidotes or reversal agents for patients with serious bleeding or need for urgent surgery. As use of the new target specific oral anticoagulants continues to increase, practitioners will need to understand both the pharmacodynamics and pharmacokinetic properties of the agents, as well as, the available literature with use of non-specific therapies to reverse anticoagulation. Four factor prothrombin complex concentrates have been available for several years in Europe, and recently became available in the United States with approval of Kcentra. These products have shown efficacy in reversing anticoagulation from vitamin K antagonists, however their usefulness with the new target specific oral anticoagulants is poorly understood. This article will review the properties of dabigatran, rivaroxaban and apixaban, as well as the limited literature available on the effectiveness of prothrombin complex concentrates in reversal of their anticoagulant effects. Additional studies are needed to more accurately define the role of prothrombin complex concentrates in patients with life threatening bleeding or who require emergent surgery, as current data is both limited and conflicting.
authors.affiliation: University of Colorado Hospital, Anschutz Inpatient Pavilion Tower 2, 12505 E 16th Ave, Mail Stop F 757, Aurora, CO 80045, USA.
authors.forename: Katrina
authors.initials: K
authors.lastname: Babilonia
authors.affiliation: University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, C238-V20 Pharmacy & Pharmaceutical Sciences, 12850 E. Montview Blvd. Room V20-1217, Aurora, CO 80045, USA.
authors.forename: Toby
authors.initials: T
authors.lastname: Trujillo
references.citation: Thromb Haemost. 2013 Jul;110(1):162-72
references.pmid: 23636219
references.citation: Thromb Haemost. 2010 Jun;103(6):1116-27
references.pmid: 20352166
references.citation: Am J Health Syst Pharm. 2012 Jul 1;69(13):1113-26
references.pmid: 22722590
references.citation: Clin Pharmacokinet. 2010 Apr;49(4):259-68
references.pmid: 20214409
references.citation: Crit Care. 2011;15(1):201
references.pmid: 21345266
references.citation: Drug Metab Dispos. 2008 Feb;36(2):386-99
references.pmid: 18006647
references.citation: N Engl J Med. 2011 Sep 15;365(11):981-92
references.pmid: 21870978
references.citation: Int J Cardiol. 2013 Oct 9;168(4):4228-33
references.pmid: 23928345
references.citation: N Engl J Med. 2012 Jan 5;366(1):9-19
references.pmid: 22077192
references.citation: J Thromb Thrombolysis. 2013 Aug;36(2):195-202
references.pmid: 23657589
references.citation: N Engl J Med. 2011 Sep 8;365(10):883-91
references.pmid: 21830957
references.citation: J Thromb Haemost. 2008 Apr;6(4):622-31
references.pmid: 18208533
references.citation: N Engl J Med. 2009 Sep 17;361(12):1139-51
references.pmid: 19717844
references.citation: Thromb Res. 2004;113(6):371-8
references.pmid: 15226091
references.citation: Ann Pharmacother. 2013 Jun;47(6):841-55
references.pmid: 23695644
references.citation: Chest. 2012 Feb;141(2 Suppl):e120S-e151S
references.pmid: 22315258
references.citation: J Thromb Haemost. 2013 Jun;11 Suppl 1:122-8
references.pmid: 23809116
references.citation: Anesthesiology. 2012 Jan;116(1):94-102
references.pmid: 22042412
references.citation: J Thromb Haemost. 2011 Jan;9(1):133-9
references.pmid: 20946166
references.citation: Br J Haematol. 2011 Dec;155(5):537-48
references.pmid: 22017416
references.citation: Crit Care Med. 2013 May;41(5):e42-6
references.pmid: 23474679
references.citation: Nat Med. 2013 Apr;19(4):446-51
references.pmid: 23455714
references.citation: N Engl J Med. 2010 Dec 23;363(26):2499-510
references.pmid: 21128814
references.citation: J Thromb Thrombolysis. 2013 Aug;36(2):187-94
references.pmid: 23512159
references.citation: Br J Haematol. 2002 Mar;116(3):619-24
references.pmid: 11849221
references.citation: Thromb Haemost. 2012 Aug;108(2):217-24
references.pmid: 22627883
references.citation: Circulation. 2011 Oct 4;124(14):1573-9
references.pmid: 21900088
references.citation: Br J Clin Pharmacol. 2010 Nov;70(5):703-12
references.pmid: 21039764
references.citation: Thromb Res. 2012 Apr;129(4):526-9
references.pmid: 22304928
references.citation: Am J Health Syst Pharm. 2013 May 15;70(10 Suppl 1):S12-21
references.pmid: 23640528
references.citation: Br J Clin Pharmacol. 2006 Nov;62(5):527-37
references.pmid: 17061960
references.citation: Am J Health Syst Pharm. 2012 Sep 1;69(17):1473-84
references.pmid: 22899742
references.citation: Interact Cardiovasc Thorac Surg. 2012 Sep;15(3):382-9
references.pmid: 22623627
references.citation: N Engl J Med. 2011 Aug 25;365(8):699-708
references.pmid: 21780946
references.citation: N Engl J Med. 2011 Dec 8;365(23):2167-77
references.pmid: 22077144
references.citation: J Thromb Haemost. 2012 Sep;10(9):1841-8
references.pmid: 22812619
references.citation: Thromb Haemost. 2012 Sep;108(3):583-5
references.pmid: 22782645
references.citation: Chest. 2012 Feb;141(2 Suppl):e152S-e184S
references.pmid: 22315259